Skip to content
x
Home
Program
Speakers
Start-up pitch
Poster presentation
Conference brochure
Impressions 2023
Sponsors and exhibitors
Stakeholder Guide
History
2022
Impressions
Program
2021
Speakers
2020
Program 2020
2019
Home
Program
Speakers
Start-up pitch
Poster presentation
Conference brochure
Impressions 2023
Sponsors and exhibitors
Stakeholder Guide
History
2022
Impressions
Program
2021
Speakers
2020
Program 2020
2019
Regulatory perspective | Current status and the post-COVID outlook for antibiotic clinical trials & approvals
Regulatory perspective | Current status and the post-COVID outlook for antibiotic clinical trials & approvals
Moderator:
John Rex, Chief Medical Officer, F2G Ltd.
Speakers:
Sumathi Nambiar – Director Division of Anti-Infective Products, Office of Infectious Diseases, FDA
Marco Cavalieri – Head of Antiinfectives and Vaccines, Safety&Efficacy Sector, EMA
Play Video
This might also be of interest for you:
Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea
, public workshop by FDA, NIAID and CDC
COVID-19: EMA sets up infrastructure for real-world monitoring of treatments and vaccines
Launch of public consultation on joint network strategy to 2025
, 6 July